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BACKGROUND: Rotavirus remains a leading cause of acute gastroenteritis in children worldwide with 
an estimated 2000 deaths each day in developing countries. Due to HIV/AIDS scourge in Kenya, it is 
possible that rotavirus-related gastroenteritis has been aggravated in adults. The Global Alliance for 
Immunizations has ranked rotavirus infection a priority for vaccine, and, to ensure its success, there is a 
need to document the local strain(s) circulating in different regions.  
METHODS: A cross-sectional study was conducted to document human rotavirus group A serotypes in 
children below 5 years and HIV-infected adults in Viwandani slum in Nairobi, Kenya. A total of 260 (128 
from children and 132 from HIV infected adults) fecal specimen samples were analyzed from August 
2012 to July 2013. Screening for rotavirus was done by antigen based enzyme immune-sorbent assay 
(ELISA), Polyacrylamide gel electrophoresis (PAGE) was used to detect rotavirus electropherotypes and 
finally genotyping was done by RT-PCR using genotype-specific primer sets targeting VP4 and VP7 
genes. 
RESULTS: Rotavirus was detected in 23% and 8% of children and adult, respectively. Prevalence was 
high in children of < 2 years and adults of > 48 years.  Long electropherotypes accounted for 80% and 
60% while short electropherotypes accounted for 20% and 40% in children and adult, respectively. The 
common globally distributed strains, G1 and G3, accounted for 60% detections while the unusual G9 
strain accounted for 80% infection in adults. G1P[8] was the common genotypic combination in 
children, accounting for 40% infection, whereas G9 [P8] accounted for 60% of the infections in adults. 
CONCLUSION: This study shows the existence of strain diversity between rotavirus circulating in 
children and adults within this study group. It further shows that as currently constituted, the 2 vaccines 
recommended for rotavirus would cover the circulating strain in Viwandani slum. Finally, there is a need 
for continuous rotavirus strain surveillance in children and a further focus on HIV infected adults. 
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Severe diarrhea due to rotavirus infection remains 
a major public health concern in Sub-Saharan 
Africa. Globally, it is estimated that rotavirus 
causes approximately 527,000 deaths per year; 
almost half of these deaths (230,000) occur in 
Sub-Saharan Africa (1). In a study covering 10 
countries in Sub-Saharan Africa, it was observed 
that >40% of all episodes of acute gastroenteritis 
affecting children under 5 years occur due to 
rotavirus infection (2). The same study observed 
that the burden of the disease was mainly
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experienced in the health sector where >40% of 
hospital admissions were due to rotavirus 
infections.  
In 2008, the World Health Organization 
(WHO) also reported rotavirus as the most 
common cause of severe diarrheal disease 
hospitalizations in young children in Africa (3). In 
fact, some studies carried out in Kenya have 
shown prevalence as high as 29% of rotavirus 
infections in hospitalized patients (4) compared to 
only 18% of outpatient cases (5). These findings 
of high burden of rotavirus in hospitalized 
children puts pressure not only on the limited bed 
capacity in many African nations but also on the 
economy, since women who contribute 
significantly to the economies would therefore 
spend a lot of time in hospitals with children away 
from work. Furthermore, the affected children also 
end up wasting a lot of time away from schools.  
Contrary to the belief of rotavirus infections 
only in children, some studies have reported 
infections in adults (6-9). Routes of transmission 
in adults have also been described (10) as 
including transmission from children to adults 
which has come out significantly in a majority of 
studies (11-13). With the high level of poverty and 
the effects of HIV/AIDS scourge in many Sub-
Saharan African countries, an increased burden of 
rotavirus infection would be expected especially in 
immunocompromised populations.  
Currently, the control of rotavirus in adults, 
especially in the immunocompromised remains a 
great challenge; however, it is expected that the 
vaccines introduced (14, 15) for  prevention of 
rotavirus infection in children, if successful, could 
provide indirect protection of these adults (16). 
However, even with the efficacy of the approved 
vaccines ranging from 89 to 98% in the 
industrialized world and parts of Latin America 
(17-20), a reduced efficacy of between 39 to 77% 
has been shown for the developing countries in 
Africa and Asia (21-23). Although the difference 
in efficacy between the developed and the 
developing world was mainly attributed to host-
related factors, (22) strain diversity still remains a 
fundamental factor especially in ensuring efficacy 
of vaccines in this part of the world. This study 
therefore aimed to document the strains of 
rotavirus circulating within a poor urban setting in 
Nairobi, Kenya, and to compare these strains 
between children and adults. 
MATERIALS AND METHODS  
 
Study Setting: This study was conducted in 2 
health facilities within Viwandani slum in Nairobi. 
This slum is located about 7 kms from Nairobi 
City Centre and extends into the Nairobi´s 
industrial area. The population here is mainly 
comprised of casual labourers working within the 
industrial area. The slum is characterized by poor 
sanitation and waste disposal. Apart from 
malnutrition and HIV/AIDS, other common public 
health challenges include diarrhoea, cholera and 
typhoid fever.  
Study population and sample material: Since 
rotavirus infection is self-limiting, stool samples 
were collected only from patients who complained 
of gastroenteritis for not more than 5 days. Upon 
receipt, the samples were transported, tested and 
analysed at the Centre for Virus Research, Kenya 
Medical Research Institute in Nairobi. Included in 
the study were children < 5 years old and HIV 
antibody positive adults. A total of 260 samples 
were collected and tested. Out of these, 128 
specimens were collected from children and 132 
from adults. 
Specimen processing:  Upon receipt, samples 
were tested by an antigen based Enzyme Linked 
Immunosorbent Assay (ELISA) and positive 
samples subjected to Poly Acrylamide Gel 
Electrophoresis (PAGE) to determine rotavirus 
electropherotypes. Further analysis of the samples 
was done in a nested RT-PCR as had been 
previously described (24). In the first reaction, 
VP4 and VP4 target specific primers 
TGGCTTCGCCATTTTATAGACA (position 11-
32) and ATTTCGGACCATTTATAACC 
(position 868-887) were used.  
In the second reaction, primer 
ATTTCGGACCATTTATAACC (position 868-
887) and a mixture of primers targeting specific 
variable regions of the VP4 and VP7, namely; the 
G1, G2, G3, G4, G6, G8, G9 and P4, P6, P8, P9 
and P10 were used.  
Ethical Clearance: This study was approved by 
the ethical committee of the Kenya Medical 
Research Institute. Permission to use samples 
from the 2 health institutions was also granted by 
the Health Department of the Nairobi City 
Council.  
Data analysis: Data were entered and analyzed in 
SPSS ver.16. Chi square test was performed to 




determine the difference in distribution patterns of 





A total of 30(23%) specimens from children and 
10(8%) (Table 1) from adults were detected 
positive by ELISA. Analysis of detections in 
children < 5 years showed that the highest 
prevalence was recorded within the age group of 7 
to 12 months followed by those within the age 
group of 13 to 24 months. The least prevalence 
was recorded for the group of <1 to 3 months 
(Figure 1). In the HIV antibody positive adults 
(Figure 2), rotavirus infection was realized in high 
frequency in the group of 49 to 58 years. The 
results showed no difference in distribution of 
rotavirus infection in the 2 groups based on 
gender.  
 




Positive Negative  
Adults 10 122 0.0002 
Children 30 98 
Adults Male 3 42 1.0000 
Females 7 80 
Children Male 14 50 0.8350 
Females 16 48 


















Fig 1: Shows the age distribution of children < 5 years. 
Highest frequency was realized for children between 6 
months to 2 years, which could be attributed to the 
development stage of the children when most of them 


















Fig 2: Frequency of rotavirus infection in adults 
{n=10} 
 
Analysis of electropherotypes revealed that 80% 
(24) of the isolated strains were long 
electropherotypes while 20% (6) of the strains 
were short electropherotypes among children. 
Long electropherotypes accounted for 60% (6) and 
short accounted for 40% (4) in adults. No mixed 
infection was detected within the 
electropherotypes. Long electropherotypes were 
therefore predominant during this study.  
It was also realized that the long 
electropherotypes did not appear to vary with age 
among children and occurred in all ages (one 
month to five years old). Short electropherotypes 





on the other hand were identified only in children 
< 2 years old.  
A total of 27 (90%) samples were genotyped for 
VP7 associated types among the 30 PAGE 
positive samples from children. Results showed 
that G1 accounted for 47% (14), followed by G9 
30% (9) and G3, 13% (4). One sample (3.7%) was 
a mixed type (G3/G9), while the remaining 2 
samples, although positive by ELISA and PAGE, 
could not be sufficiently typed. Other genotypes 
including G2, G4 and G8-type viruses were not 
detected among this group of samples. On the 
other hand, results for VP4 associated types 
showed that 25(83.3%) of the 30 PAGE positive 
samples from children could sufficiently be typed. 
Only 2 P types were shown to be in circulation 
with P[6] accounting for 6.7% (2) and P[8] 
accounting for 77% (23). Two (6.7%) samples had 
mixed (P[6]/P[8])  strains while 3 (10%) could not 
efficiently be typed. P [9] or P[10] type viruses 
were not detected.  
Throughout the study, the long 
electropherotypes were always associated with G1 
and G9 genotypes, whereas the short 
electropherotypes were associated with genotype 
G3. 
During the typing of assays, it was observed 
that a specific G type could always be correlated 
to a P type; namely, G1, and G3 always coexisted 
with P[8], while G9 was found to associate with 
P[6] or P[8]. Overall, G1 P[8] was recorded as the 
most common in children accounting for 44% of 
infections while G9[P6] at 40% was the most 
common in adults (Table 2). 
 
Table 2:  Prevalence of rotavirus genotypes detected in adults and children (n = 40) 
 




(N=10) (%)  
Total  
(N= (40) (%) 
Common types     
G1P[8] 11(37) 0 11(27.5) 
G9P[8] 5(16) 4(40) 9(22.5) 
G3P[8] 6(20) 3(30) 9(22.5) 
Uncommon types    
G9P[6] 3(10) 2(20) 5(12.5) 
G1P[4] 0 0 0 
Mixed infection 2(7) 0 2(5) 
Non typeable    
G* - P** 0 0 0 
G** – P* 1(3) 0 1(2.5) 
G* - P* 2(7) 1(10) 3(7.5) 




This study reports a prevalence of 23% and 8% of 
rotavirus infection in children below 5 years and 
HIV infected adults, respectively. It further reports 
a prevalence of 40% circulation of G1P[8] in 
children and 60% circulation of G9P[8] in adults.   
The findings regarding rotavirus prevalence 
in children reflects previous results which reported 
rotavirus in 18% in outpatient setting (5) and 30% 
in an inpatient setting (4). The burden of rotavirus 
infection in children below 5 years in Africa has 
been well elucidated in other studies (2). In our 
study within this age group, rotavirus infection 
was most prevalent in children in between 7-12 
months, only equivalent to those between 13-24 
and 25-60 months combined. Overall, children 
under 1 year contributed to over 17/30 (57%) of 
positive cases, and over 24/30 (80%) of them had 
rotavirus diarrhoea at the age of 2 years. This 
finding is a direct contradiction to the findings of 
Nokes and colleagues (4) which found a higher 
prevalence among children aged 3-5 years. The 
difference may be attributed mainly to the settings 




of the studies. The age group with the high 
prevalence of infection in our study was 
comprised of children either crawling or just 
learning to walk and as such would have a high 
risk for fecal oral transmission as they eat 
anything from the ground or suckle their fingers. 
From our observation of the conditions in 
Viwandani slum, it is unlikely that the care-givers 
spend time with the children (since a lot of time is 
taken for casual jobs in the neighboring up-market 
estates). As a result children are  left under the 
care of the neighbors or underage female relatives. 
Even within the facility, it is more likely to test 
only children above 3 years for gastroenteritis 
related pathogens compared to those below 2 
years since those below this age normally undergo 
empiric management (based on clinical 
symptoms) and rehydration therapy using the oral 
rehydration salts. This could also explain the 
results of Noke’s study where 224 cases were 
tested for the group between 3-5 years compared 
to only 84 cases tested for the group between 0-2 
years. In their work, Temu and colleagues (25) 
also showed high prevalence of rotavirus infection 
among children below 2 years in Tanzania. As had 
been anticipated, there was no significant 
difference in the rate of infection between male 
and female children. 
To the best of our knowledge, there is 
currently very little or no information on the 
prevalence of rotavirus infection among Kenyan 
adults, and as such, we are unable to relate our 
findings within this population to any similar 
study in Kenya. Although,  our study in adults was 
carried out in HIV antibody positive adults. The 
data presented here did not evaluate among other 
things the immune status (through CD4 counts) or 
the viral load of the patients prior to collection of 
samples for analysis. Therefore, as such we cannot 
conclusively show that infection by rotavirus was 
as a result of AIDS disease. Further, we also note 
that although the highest prevalence within this 
group was between the age of 48-59 years (50% of 
the total adult cases), the data (n = 10) was also 
very small for conclusive evaluation of low 
immune status within this group. We can, 
however, hypothesize that the majority of women 
in poor settings in Kenya within this age group, 
currently remain or take care of their 
grandchildren as the mothers of the children (in 
many cases single mothers) look for their 
livelihoods. The latter assertion is also 
strengthened by the fact that up to 70% of 
rotavirus infections in adults were among women. 
The finding of rotavirus among women could also 
point to transmission from children to adults (10).  
Our findings concerning rotavirus infection in 
both children and adults, coupled with other 
studies which have mainly focused on the 
prevalence of the disease, indicate that the burden 
of rotavirus infection in both children and adults to 
public health cannot be underestimated. This high 
burden of infection in children, and availability of 
effective rotavirus vaccines (14, 15, 18, 23) to 
prevent childhood deaths and hospitalizations, 
underscores the need to introduce these vaccines 
in the national programs on immunization by 
African governments in order to save the lives of 
children. So far, 5 African countries have 
successfully introduced rotavirus vaccination in 
their vaccine schedules, with Kenya listed as one 
of those African countries eligible for GAVI 
(Global Alliance for Vaccine Initiative) in 2014 
(26). Even as African governments prepare to roll 
out rotavirus vaccines within the national 
childhood immunization programs, evaluation of 
these vaccines post licensure remains critical. Of 
special importance is the continuous surveillance 
of the circulating strains, as this information will 
guide on policy decision making on the type of 
vaccine. 
Three fundamental questions still remain in 
regard to introduction of these vaccinations in 
large scale in Africa: 1) what will be the serotype 
specific efficacy of these vaccines in regard to 
strain variation in Sub-Saharan Africa? 2) Would 
we expect an emergence of unusual strain or 
strains escaping vaccine protection? 3) Will 
significant increases in strain-related disease 
burden occur after the roll out of rotavirus 
vaccinations? 
During this study, we found out that G1 [P8] 
and G9[P8] (which were both associated with long 
electropherotypes) were the most prevalent in 
Viwandani slum. A study by WHO African 
Rotavirus Surveillance Network (2) covering 8 
countries showed that G1 and G2 were detected 
routinely. A closer look at their data also reveals 
that in Kenya, G1 to G9 were detected with 
G1[P8] accounting for the highest (23%) followed 
by G8[P6] (15%) and G9[P8] (8%) of the top 3 
strains. The finding of G1[P8] as the most 





prevalent in Viwandani indicates minimum 
reassortment of the virus within this population, 
and any vaccine targeting the major circulating 
strains in Kenya would be beneficial to this 
community. In this study, however, we could not 
detect G2 and G8 strains-an indication of a 
possible strain variation within different regions in 
the country. Just as Mwenda and colleagues found 
out, we also found mixed genotypes and a 
significant number (7% for G-type and 10% for P-
type) could not be typed among the children. The 
presence of untypeable strains could point towards 
the existence of non-human rotavirus strains in 
circulation (27). Alternatively, the results could 
point towards the importance of revising the 
common primers currently used in RT-PCR during 
human rotavirus typing.  
Two vaccines, a monovalent vaccine-Rotarix 
(Glaxosmithkline) and a pentavalent vaccine-
Rotateq (Merck & Co Inc.), have been licensed. 
Rotarix as it is, provides cross protection to G1, 
G3, G4 and G9 whereas Rotateq provides cross 
protection to G1, G2, G3 and G4 viruses (28). It is 
therefore notable that the question of whether 
vaccine providing cross protection against all 
strain variants in Africa still remains pertinent. 
Although these vaccines have shown high efficacy 
in the western world and Latin America, a reduced 
efficacy has been reported in African and Asia 
countries. Further, 3 longitudinal strain 
surveillance studies done before and after routine 
childhood vaccinations have shown an upsurge of 
different strains. In their study, Carvalho-Costa 
and colleagues (29) noted a predominance of 
G2[P4] strain within 2 years after the introduction 
of a single strain vaccine in Brazil. On the other 
hand, Hull and colleagues noted an upsurge in 
G3[P8] strains after the introduction of a 
pentavalent vaccine (30). Further, a study done in 
Australia using the two types of vaccines (31) 
showed a higher prevalence of G2[P4] in the states 
that exclusively used the monovalent vaccine as 
opposed to G3[P8] strain that had a high 
prevalence in the states that used a pentavalent 
vaccine. Although the authors are cautious and 
warn against any conclusion with regard to the 
role of vaccination in the upsurge of the observed 
strains, their findings underscore the need for 
continuous strain surveillance and epidemiological 
studies prior to and post vaccine introduction for 
mass vaccination, especially in Africa where strain 
diversity remains a major concern. 
A number of limitations were observed in our 
study, namely, lack of CD4 or HIV viral load in 
adults to conclusively link rotavirus infection to 
HIV infection. Further, we are unable to show 
whether there was any relationship between the 
adults in our study and the children; hence, the 
study cannot completely justify transmission 
within the groups. The study was also done within 
a small slum in Nairobi’s urban setting and hence 
the findings cannot be extrapolated to cover strain 
diversity in the entire country. 
In conclusion, our study shows the existence 
of strain diversity between adults and children 
circulating in Viwandani slums and that these 
strains would potentially be covered by the 2 
vaccines recommended for rotavirus prevention in 
children. Our results have also shown the 
prevalence in HIV infected adults. We further 
recommend that continuous rotavirus strain 
surveillance be carried out in other slums in 
Nairobi, and the focus should also include HIV 
positive adults, as this will help elucidate the risk 
of children-to-adult or adult-to-children 
transmission. The data generated in future studies 
would also present a picture of whether indirect 
protection of adults would be feasible with the 
vaccination of children.    
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